Clinical Validation – Prostate Cancer

Yamoah, K., et al. Novel biomarker signature that may predict aggressive disease in African-American men with prostate cancer. Journal of Clinical Oncology, 2015; DOI: 10.1200/JCO.2014.59.8912.

Ross A.E., et al. Tissue Based Genomics Augment Post-Prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2015; DOI: 10.1016/j.eururo.2015.05.042

Den, R.B., et al. A genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. Journal of Clinical Oncology 2015; 33:944-951.

Cooperberg, M.R., et al. Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. European Urology, 2015 Feb; 67(2):326-333.

Klein, E. et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. European Urology 2015; 67(4): 778-786.

Den, R. et al., A Genomic Prostate Cancer Classifier predicts Biochemical Failure and Metastasis in Patients Following Post Operative Radiation Therapy. Int J Radiat Oncol Biol Phys., 2014 Aug 1; 89(5): 1038-46.

Ross, A.E., et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer and Prostatic Diseases, 2014, 17, 64-69.

Karnes, R.J., et al. Validation of a Genomic Classifier that Predicts Metastasis Following Radical Prostatectomy in an At Risk Patient Population. J Urol, 2013 Dec, 190(6), 2047-2053.

Den, et al. Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy. J Clin Oncol 33, 2015 (suppl; abstr 5016).

Clinical Utility

Lobo, J.M., et al., Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. PLoS One. 2015 Apr 2;10(3):e0116866. doi: 10.1371/journal.pone.0116866.

Nguyen, P., et al., Impact of a Genomic Classifier of Metastatic Risk on Post-Prostatectomy Treatment Recommendations by Radiation Oncologists and Urologists. Urology.2015; 86(1): 35-40. Featured on the cover of Urology July 2015

Michaelopolous, S., et al., Influence of a genomic classifier on postoperative treatment decisions in high-risk prostate cancer patients: Results from the PRO-ACT study. Curr Med Res Opin 2014; 30(8):1547-56.

Badani, K., et al., Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. British Journal of Urology Intl 2014; 115(3): 419-429

Badani, K., et al. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget, 2013. 4(4), 600-609.

Analytical Validation and other Supporting Publications

Tomlins, S.A., et al. Characterization of 1,577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathological Insights into Molecular Subtypes. European Urology. 2015; doi:10.1016/j.eururo.2015.04.033.

Ross, A.E., et al. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. 2015; DOI: 10.1016/j.eururo.2015.04.016.

Alshalalfa, M., et al. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. Biology of the Cell, 2015; DOI: 10.1111/boc.201400097.

Alshalalfa, M., et al. Clinical and Genomic Analysis of Metastatic Prostate Cancer Progression in a Background of Post-Operative Biochemical Recurrence. British Journal of Urology Intl, 2015; DOI: 10.1111/bju.13013.

Erho, N., et al., Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy. PLoS One. 2013 Jun 24;8(6):e66855.

Erho, N. et al. Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer. Journal of Oncology. 2012;2012:541353.

Abdueva, D., et al. Quantitative Expression Profiling in Formalin-Fixed Paraffin-Embedded Samples by Affymetrix Microarrays.  The Journal of Molecular Diagnostics:2010;12(4):409-17.

Genomic Discovery

Chakravarty, D. et al.The ​oestrogen receptor alpha-regulated lncRNA ​NEAT1 is a critical modulator of prostate cancer. Nature Communications, 2014 Nov 21;5:5383, doi:10.1038/ncomms6383

Prensner, J.R. et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncology, Early Online Publication, 2014 Nov 17, doi:10.1016/S1470-2045(14)71113-1.

Lalonde, E. et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, Early Online Publication, 2014 Nov 13, doi:10.1016/S1470-2045(14)71021-6.

Prensner, JR., et al. The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.​ Oncotarget. 2014 Mar 23.

Kaushik, AK., et al. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014 Feb 7;13(2):1088-100.

Prensner, JR., et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 29 Sep 2013.

Wiseman, SM., et al. Whole-transcriptome profiling of thyroid nodules identifies expression-based signatures for accurate thyroid cancer diagnosis. J Clin Endocrinol Metab. 2013 Oct;98(10):4072-9.

Hurley, PJ., et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14977-82.

Vergara, IA., et al. Genomic “dark matter” in prostate cancer: exploring the clinical utility of ncRNA as biomarkers. Frontiers in Genetics. 2012; 3:23.

Bladder Cancer

Jager, W., et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. Advance Publications 2015.

Seiler, R., et al. p53-ness is associated with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin. J Clin Oncol 33, 2015 (suppl; abstr 4512).

Mitra, A.P., Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder CancerJNCI J Natl Cancer Inst (2014) 106 (11): dju290 doi: 10.1093/jnci/dju290.

Seiler, R., et al. Can bladder cancer gene expression signatures be used to predict lymph node metastasis at the time of radical cystectomy? AUA 2015 Abstract.